Product Information

ENOXAPARIN 300 MG/3 ML VIAL is a generic product labeled by Sanofi-Aventis U.S. LLC, priced at $9.9755 per ML under NDC 00955101601. Its NADAC has been published 478 times since Dec 18, 2013.

FDA first approved this application on Mar 29, 1993. Its Orange Book therapeutic-equivalence code is AP.

The High Outlier badge above means this manufacturer's average price in the enoxaparin sodium market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

ENOXAPARIN 300 MG/3 ML VIAL

enoxaparin sodium
$9.9755per ML
High Outlier

Strength

300 mg/3mL

NDC

00955101601

Classification

Generic

Dosage Form

INJECTION

Route

SUBCUTANEOUS

Effective Date

10/21/2026

Active Ingredients

ENOXAPARIN SODIUM

Approval Type

Authorized Generic (NDA)

FDA Application

NDA020164

FDA Approved

3/29/1993

TE Code

AP

On Market Since

10/3/2011

Pharmacological Classes

Heparin
Low-Molecular-Weight
Low Molecular Weight Heparin

Price Statistics

The NADAC for ENOXAPARIN 300 MG/3 ML VIAL has been published 478 times since Dec 18, 2013, and over the history we have for it it has declined 80.3%. The table below summarizes its recorded NADAC range and movement.

Current price$9.9755 per ML
All-time high$68.5340 (Feb 11, 2015)
All-time low$9.8724 (Sep 23, 2026)
52-week high$11.6405
52-week low$9.8724
Median price$14.5810
Average price$24.0420
Largest weekly change-45.9% (Aug 23, 2017)
Weeks tracked478
Tracking sinceDec 18, 2013

Price History

1W

0.0%

1M

+1.0%

3M

+0.5%

6M

-9.1%

1Y

-12.7%

3Y

-25.7%

5Y

-20.2%

All

-80.3%

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of ENOXAPARIN 300 MG/3 ML VIAL?

The current National Average Drug Acquisition Cost (NADAC) for ENOXAPARIN 300 MG/3 ML VIAL, manufactured by Sanofi-Aventis U.S. LLC, is $9.9755 per ML (NDC 00955101601), effective Nov 11, 2026.

How has the price of ENOXAPARIN 300 MG/3 ML VIAL changed over time?

Over the history we have for it, the NADAC for ENOXAPARIN 300 MG/3 ML VIAL has declined 80.3%. It has been tracked across 478 weekly CMS publications since Dec 18, 2013.

What are the highest and lowest recorded NADAC prices for ENOXAPARIN 300 MG/3 ML VIAL?

Since Dec 18, 2013, the NADAC for ENOXAPARIN 300 MG/3 ML VIAL has ranged from a low of $9.8724 (Sep 23, 2026) to a high of $68.5340 (Feb 11, 2015), with a median of $14.5810 per ML.

Are there cheaper alternatives to ENOXAPARIN 300 MG/3 ML VIAL?

Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ENOXAPARIN 300 MG/3 ML VIAL, is $9.8724 per ML — about 1% below ENOXAPARIN 300 MG/3 ML VIAL.

Who manufactures ENOXAPARIN 300 MG/3 ML VIAL?

ENOXAPARIN 300 MG/3 ML VIAL (NDC 00955101601) is labeled by Sanofi-Aventis U.S. LLC, and CMS classifies it as a generic product.